513 related articles for article (PubMed ID: 19491900)
41. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
Erkizan HV; Uversky VN; Toretsky JA
Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
[TBL] [Abstract][Full Text] [Related]
42. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
43. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ
Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142
[TBL] [Abstract][Full Text] [Related]
44. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Hahm KB; Cho K; Lee C; Im YH; Chang J; Choi SG; Sorensen PH; Thiele CJ; Kim SJ
Nat Genet; 1999 Oct; 23(2):222-7. PubMed ID: 10508522
[TBL] [Abstract][Full Text] [Related]
45. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
46. Mithramycin A Radiosensitizes EWS:Fli1
Lin MY; Damron TA; Oest ME; Horton JA
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1454-1471. PubMed ID: 33373655
[TBL] [Abstract][Full Text] [Related]
47. Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors.
Loganathan SN; Tang N; Holler AE; Wang N; Wang J
Mol Cancer Ther; 2019 May; 18(5):929-936. PubMed ID: 30926641
[TBL] [Abstract][Full Text] [Related]
48. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
49. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
50. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
[TBL] [Abstract][Full Text] [Related]
51. Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma.
Knezevich SR; Hendson G; Mathers JA; Carpenter B; Lopez-Terrada D; Brown KL; Sorensen PH
Hum Pathol; 1998 Mar; 29(3):289-94. PubMed ID: 9496833
[TBL] [Abstract][Full Text] [Related]
52. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
Agra N; Cidre F; García-García L; de la Parra J; Alonso J
PLoS One; 2013; 8(6):e66281. PubMed ID: 23750284
[TBL] [Abstract][Full Text] [Related]
53. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
54. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
[TBL] [Abstract][Full Text] [Related]
55. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.
Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR
Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219
[TBL] [Abstract][Full Text] [Related]
56. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
[TBL] [Abstract][Full Text] [Related]
57. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
[TBL] [Abstract][Full Text] [Related]
59. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
60. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
